28 injections will be collected! 10 provinces to collect "lift" the price reduction tide.

32 over 1 billion varieties! Shandong belt purchase amplification recently, Shandong Provincial Health Insurance Bureau held a consultation meeting on 40 proposed volume procurement varieties, discussed the specific bidding procurement rules, including quality layering, price reduction requirements, winning regional selection, etc., the plan to start collection in July.
a fierce price war is coming! Previously, Shandong Provincial Health Insurance Bureau issued a notice on April 24, has been in accordance with the principle of high clinical use, high procurement amount, full competition, identified 40 centralized volume procurement of drug varieties.
-meter net data show that 40 varieties (105 standards) in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal sales of more than 1 billion yuan in 2019 32.
from the drug category, the digestive system and metabolic drugs involved in 15 varieties, 6 varieties for nervous system drugs, 4 varieties for blood and hematopoietic system drugs, anti-tumor and immunomodulators, cardiovascular system drugs, systemic hormone preparations (without sex hormones), miscellaneous products each have 3 varieties.
minet data show that in 2019 China's public medical institutions terminal digestive system and metabolic drugs sales after the whole body anti-infective drugs, the second major drug category.
40 band-purchased drug categories distribution Minnet network consistency evaluation database shows that of the 40 varieties purchased with volume in Shandong Province, the proportion of non-rated varieties reached 85%, only 6 over-rated varieties, respectively, the baritise metolol tablets, glycen tablets, benzene sulfonyaquol ammonium injection, doso tea injection, Oshalali injection, injection of sodium.
these varieties of over-rated enterprises in the tender than other generic pharmaceutical companies have an advantage.
these evaluated varieties will be divided into the first level with the original research drugs, expired patented drugs, reference formulations, Chinese drug list editing sets, as well as drugs exported to the United Kingdom, France, China, Canada, the United States, Australia and Japan.
6 rated varieties 28 injections! Heng Rui, Osaikang, Yang Zijiang... Heavy varieties in Shandong Province, the volume of procurement of 40 varieties, involving the best-selling antihypertensive drugs, proton pump inhibitors, contrast agents, narcotics, anti-tumor drugs, antithrombotic drugs and so on.
from the dosage form, 40 varieties of 12 for oral preparations (oral changean form, slow release control release dosage form), 28 varieties for injections.
the sales of 40 band-purchased varieties in Shandong Province, 9 of the 12 oral preparations will have end-sales of more than 1 billion yuan in 2019 in public medical institutions in China.
, the sales of the left ammonia chlorite oral regular release agent type (2.5mg, 5mg) was close to 5,028 million yuan, Shi Huida Pharmaceutical Group occupied 42.22% of the market share, the sales of the rebella oral changxuan dosage form (10mg, 20mg) was close to 4,924 million yuan, and Jichuan Pharmaceuticals accounted for 37.07% of the market share.
23 of the 28 injections sold more than 1 billion yuan in 2019 at public medical facilities in China.
, Omeprazole injections (20mg, 40mg, 60mg) were close to 6.678 billion yuan, with Osekang accounting for 41.58 percent of the market share, and radorazole injections (40mg, 60mg, 80mg) sales were 6.197 billion yuan, and Yangzijiang Pharmaceutical Group accounted for 29.60 percent of the market share.
of concern is that the domestic has been approved for the listing of six proton pump inhibitors, omeprazole, Lansoola, pilatea, rebella, aiomeprazole are on the list, Epraazole only one production, due to insufficient competition and not included in the collection.
2019 China's public medical institutions terminal 28 injection sales TOP1 enterprises, Hengrui Pharmaceuticals, Yangzijiang Pharmaceutical Group, FesenYuskabi, Sanofi, Pfizer, Aspen have 2 varieties of sales first, Ruiyang Pharmaceuticals has 3 varieties of sales first.
sales of iodized salsalin injections and benzene shun aquku ammonium injections were RMB3.685 billion and RMB 2,961 million, respectively, with Hengrui Pharmaceuticals accounting for 50.48 percent and 69.32 percent of the market share, respectively.
sales of iodine sea alcohol injections and pyroprazole injections were 3.682 billion yuan and 6.197 billion yuan, respectively, with Yangzijiang Pharmaceutical Group accounting for 51.92 percent and 29.60 percent of the market share, respectively.
collection everywhere flowering, 10 provinces have been announced with the volume of procurement varieties of the provinces into 2020, the national volume procurement continues to promote, the third batch of collection varieties list has been in the pipeline, provincial and local drug production is also flowering everywhere.
drug-belt procurement into the normal, "band procurement as a principle, non-quantity procurement is the exception" recruitment policy system is being formed.
so far, at least eight provinces, including Guangxi, Hebei, Fujian, Hunan, Shanxi, Jiangxi, Shandong and Qinghai, have issued a list of concentrated tape procurement varieties, and Jiangsu, Yunnan and other provinces have announced that they will carry out provincial drug-belt procurement.
, in addition, Sanming Alliance, Wuhan, Puyang, Jinhua and other districts / municipalities have also carried out local drug volume procurement.
although the collection of drugs and the number of different, but antimicrobialdrugs, proton pump inhibitors, slow disease drugs and so on have been on the list many times.
this year by the new crown pneumonia outbreak, the national health insurance control fee pressure intensified, provincial collection era accelerated to come, clinical use of large, procurement amount, full competition for drugs bear the brunt.
June 5, 2019, the National Health and Care Commission and other nine ministries jointly issued a letter, clearly promote the local non-over-evaluation of drug production procurement.
before, the national belt procurement varieties to consistency evaluation as the threshold, the election of generic drug companies relatively few, but many varieties have fallen below the floor price, non-evaluated varieties of the volume of procurement due to fierce competition, in the provinces under the continuous exploration or will set off a wave of price reduction.
source: Minnet database, all over the drug tender procurement platform original title: 28 injections will be collected! Heng Rui, YangZijiang... Heavyweight varieties are targeted, 10 provinces to collect "lift" price reduction tide.